Dollar edges higher ahead of Fed minutes; sterling gains after CPI increase
In a recent transaction, Tyler Brian S., the Chief Executive Officer of McKesson Corp (NYSE:MCK), sold a significant portion of his holdings in the company. The healthcare services giant, currently valued at $88.7 billion, has demonstrated strong financial health according to InvestingPro analysis, with its stock trading near its 52-week high of $731. According to a filing with the Securities and Exchange Commission, the CEO sold 19,370 shares of McKesson’s common stock on June 6, 2025, at a price of $705.93 per share. This sale, which was conducted under a pre-established trading plan, amounted to a total value of approximately $13.67 million. The transaction comes as McKesson has delivered impressive returns, with a 22% gain over the past year and maintaining dividend payments for 32 consecutive years.
Following this transaction, Tyler Brian S. retains direct ownership of 51,243 shares in the company. Additionally, he holds an indirect ownership of 214.9469 shares through the McKesson Corporation 401(k) Retirement Savings Plan. The sale was executed as part of a plan adopted on November 8, 2024, in compliance with Rule 10b5-1(c), which allows company insiders to set up a predetermined schedule for selling stocks. Discover 14 more exclusive insights about McKesson’s financial outlook and valuation with InvestingPro’s comprehensive research report.
In other recent news, McKesson Corporation reported its fiscal fourth-quarter earnings, surpassing Wall Street’s expectations with adjusted earnings per share (EPS) of $10.12, beating the forecast of $9.81. However, the company faced a revenue shortfall, reporting $90.82 billion against a projected $93.48 billion. Despite the mixed results, McKesson’s management remains optimistic, maintaining a long-term EPS growth outlook of 12%-14%. In a strategic move, McKesson completed the acquisition of a 70% controlling interest in Core Ventures for approximately $2.49 billion, aiming to enhance community-based oncology care. This acquisition is expected to contribute significantly to the company’s growth in the U.S. Pharmaceutical (TADAWUL:2070) segment. Jefferies analyst Rob Dickerson has raised McKesson’s stock target to $800, maintaining a Buy rating, citing the company’s robust financial performance and favorable forward guidance. The company also announced plans to separate its Medical (TASE:BLWV) Surgical segment into an independent entity, focusing on enhancing operational efficiency. These developments underscore McKesson’s commitment to strengthening its position in the healthcare services sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.